ArticleInternal medicine journal2026
Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost analysis from a tertiary-care, multidisciplinary MAFLD clinic.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPatients with metabolic (dysfunction)-associated fatty liver disease (MAFLD) are frequently multimorbid, putting upward pressure on healthcare costs compared to other liver diseases. As Australian data are limited on expenditures in managing MAFLD, we evaluated hospital-related costs and predictors of costs in patients managed in a dedicated MAFLD clinic.
methodsWe conducted a retrospective review of adults attending a MAFLD clinic in Melbourne, Australia between January 2017 and December 2020. A control cohort of chronic hepatitis B (CHB) patients provided disease context. We analysed direct healthcare utilisation and costs categorised by specialty, hospital setting and fibrosis stage. Multivariate Poisson regression identified independent predictors of increased healthcare utilisation. Multivariate linear regression analysis identified independent predictors of healthcare cost.
resultsA total of 310 MAFLD and 261 CHB patients were followed up over a median 1.93 vs 4.06 years (P < 0.001). Advanced fibrosis/cirrhosis (F3-4) represented 26% MAFLD patients and 9% CHB patients accounting for 54.9% and 18.2% total expenditure respectively. Inpatient utility was greater in MAFLD compared to CHB (6.1% vs 0.4%, P < 0.001), as was proportion of hospitalisation costs (48.3% vs 0.8%, P < 0.001). Independent predictors of cost in MAFLD were obstructive sleep apnea (P < 0.01), cardiovascular disease (P = 0.04) and F3-4 (P < 0.001), which also predicted liver-related outpatient appointments and radiology (P < 0.001 for both).
conclusionsThe greatest healthcare-related costs for MAFLD clinic patients are incurred through hospitalisation, with F3-4 predicting a disproportionately high economic burden. Our findings demonstrate the association between metabolic comorbidities and liver disease progression in MAFLD, highlighting a research gap of integrated care provision to optimise resource allocation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.